Sales of Johnson & Johnson worldwide 2011-2023, by segment
The pharmaceutical segment of Johnson & Johnson was the company’s strongest segment over the last years, generating nearly 55 billion U.S. dollars in sales globally in 2023. The rise of pharmaceuticals as the company’s leading segment began in 2013, when it was about even with the medical devices and diagnostics segment for the first time. Johnson & Johnson’s third pillar, until 2022, was the consumer health segment.
Johnson & Johnson company overview
New Jersey-based Johnson & Johnson is a global diversified healthcare company, with the pharmaceutical business becoming increasingly dominant over time. Within Johnson & Johnson’s pharmaceutical segment, oncology and immunology are the major therapeutic areas. But Johnson & Johnson also has another strong business segment: medical technology. In fact, this segment ranks J&J among the world’s top 10 medical technology companies.
The company’s pharmaceutical segment
Since 2013, the pharmaceutical business showed significant growth among J&J’s segments. That the company shows particular engagement in this field is also visible by the size of its R&D pipeline which is one of the largest within the pharma industry, as of 2023. Five companies showed a higher count of drugs in the pipeline. Johnson & Johnson was ranked seventh worldwide based on the number of originated drugs, as of the same year. These developments are comprehensible when taking into account the company’s share of revenue which is invested into research and development.
Johnson & Johnson company overview
New Jersey-based Johnson & Johnson is a global diversified healthcare company, with the pharmaceutical business becoming increasingly dominant over time. Within Johnson & Johnson’s pharmaceutical segment, oncology and immunology are the major therapeutic areas. But Johnson & Johnson also has another strong business segment: medical technology. In fact, this segment ranks J&J among the world’s top 10 medical technology companies.
The company’s pharmaceutical segment
Since 2013, the pharmaceutical business showed significant growth among J&J’s segments. That the company shows particular engagement in this field is also visible by the size of its R&D pipeline which is one of the largest within the pharma industry, as of 2023. Five companies showed a higher count of drugs in the pipeline. Johnson & Johnson was ranked seventh worldwide based on the number of originated drugs, as of the same year. These developments are comprehensible when taking into account the company’s share of revenue which is invested into research and development.
